Tillkännagivande • Apr 17
Rhythm Biosciences Limited has completed a Follow-on Equity Offering in the amount of AUD 3.766801 million. Rhythm Biosciences Limited has completed a Follow-on Equity Offering in the amount of AUD 3.766801 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 18,834,007
Price\Range: AUD 0.2
Transaction Features: Subsequent Direct Listing Tillkännagivande • Dec 02
Rhythm Biosciences Limited has completed a Follow-on Equity Offering in the amount of AUD 3.748902 million. Rhythm Biosciences Limited has completed a Follow-on Equity Offering in the amount of AUD 3.748902 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 3,333,332
Price\Range: AUD 0.09
Discount Per Security: AUD 0.0054
Security Features: Attached Options
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 38,321,133
Price\Range: AUD 0.09
Discount Per Security: AUD 0.0054
Security Features: Attached Options
Transaction Features: Subsequent Direct Listing Tillkännagivande • Aug 18
Rhythm Biosciences Limited has filed a Follow-on Equity Offering in the amount of AUD 3.748902 million. Rhythm Biosciences Limited has filed a Follow-on Equity Offering in the amount of AUD 3.748902 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 3,333,332
Price\Range: AUD 0.09
Discount Per Security: AUD 0.0054
Security Features: Attached Options
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 38,321,133
Price\Range: AUD 0.09
Discount Per Security: AUD 0.0054
Security Features: Attached Options
Transaction Features: Subsequent Direct Listing Tillkännagivande • Mar 18
Rhythm Biosciences Limited Appoints Todd Perkinson as Chief Financial Officer Rhythm Biosciences Limited announced the appointment of Mr. Todd Perkinson as Chief Financial Officer (CFO) effective 18th March 2025. Mr. Perkinson brings a wealth of experience in executive leadership, financial management and business transformation. With a proven track record across various industries, Todd has successfully led major mergers and acquisitions, optimised operational efficiency and driven significant revenue growth. Most recently, at AdNeo Limited, Todd spearheaded a business turnaround, delivering multi-million-dollar improvements of EBITDA and NPAT year-over-year. Under Todd's leadership, the company secured a multi-million-dollar capital raise, completed the acquisition of Oliver Grace and expanded its U.S. mentoring subsidiary by over 200%. Prior to this, Todd played a pivotal role in the $100 million sale of Vault Intelligence to Damstra Holdings, where he oversaw cost reductions, revenue growth and strategic partnerships across the APAC region. In addition to his corporate leadership, Todd has demonstrated exceptional strategic foresight in driving business transformations and process improvements at organizations including Emerge Aotearoa, Nimble Money and Royal District Nursing Service. A Chartered Accountant with a Bachelor of Commerce and Administration from Victoria University of Wellington, Todd brings a strong analytical and results-driven approach to every role. Tillkännagivande • Nov 27
Rhythm Biosciences Limited has completed a Follow-on Equity Offering in the amount of AUD 3.5 million. Rhythm Biosciences Limited has completed a Follow-on Equity Offering in the amount of AUD 3.5 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 35,000,000
Price\Range: AUD 0.1
Discount Per Security: AUD 0.006
Security Features: Attached Options
Transaction Features: Subsequent Direct Listing Tillkännagivande • Nov 19
Rhythm Biosciences Limited has filed a Follow-on Equity Offering in the amount of AUD 3.5 million. Rhythm Biosciences Limited has filed a Follow-on Equity Offering in the amount of AUD 3.5 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 35,000,000
Price\Range: AUD 0.1
Discount Per Security: AUD 0.006
Security Features: Attached Options
Transaction Features: Subsequent Direct Listing Tillkännagivande • Nov 11
Rhythm Biosciences Ltd Appoints Gavin Fox-Smith as Independent Non-Executive Director Effective 2 December 2024 Rhythm Biosciences Ltd. announced the appointment of Mr. Gavin Fox-Smith as a new, Independent Non-Executive Director effective 2 December 2024. Mr. Fox-Smith is one of Australia's most experienced and respected leaders in the MedTech industry, with a broad experience encompassing both large multinational and smaller, domestic companies. Gavin has been a leader and champion of Medical Technology across Australia/NZ and Asia. He has also played lead Governance and Executive roles in Industry Bodies, Innovation Initiatives and Not for Profit Boards. Gavin is strong advocate for Gender Equality and Indigenous Engagement. His career spans over 35 years, previously holding the position of Managing Director Australia/NZ and Vice President Asia Pacific for Johnson & Johnson Medical Devices, Chair of the Medical Technology Association of Australia, Governor of American Chamber of Commerce, Co-Founder/Chair of Macquarie Park Business Coalition (in partnership with United Way) and Australian Co-Chair of the Health Technology Sector Group of the Australia/NZ Leadership Forum. Gavin is currently transitioning out of his executive CEO role at Omnigon, a private Australian company in the Ostomy Care market. He is at this time, Chair of ANDHealth (Australia's National Digital Health Initiative), Board Director for Bowel Cancer Australia and Board Director for SAN Foundation. Gavin is a proud member of the Champions of Change Coalition STEM/Health group and serves as Ambassador for Rotary Oceania Medical Aid for Children (ROMAC). Gavin is a Graduate of the Australian Institute of Company Directors and recently completed the AICD Boardroom Mastery program. Tillkännagivande • Sep 10
Rhythm Biosciences Limited, Annual General Meeting, Nov 20, 2024 Rhythm Biosciences Limited, Annual General Meeting, Nov 20, 2024. New Risk • Sep 01
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$6.2m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$6.2m free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 20% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (13% increase in shares outstanding). Revenue is less than US$5m (AU$1.7m revenue, or US$1.2m). Market cap is less than US$100m (€9.44m market cap, or US$10.4m). New Risk • Aug 14
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 26% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (14% increase in shares outstanding). Revenue is less than US$5m (AU$2.1m revenue, or US$1.4m). Market cap is less than US$100m (€10.2m market cap, or US$11.2m). New Risk • Jul 19
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: €9.01m (US$9.80m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 26% per year over the past 5 years. Market cap is less than US$10m (€9.01m market cap, or US$9.80m). Minor Risks Share price has been volatile over the past 3 months (7.8% average weekly change). Shareholders have been diluted in the past year (15% increase in shares outstanding). Revenue is less than US$5m (AU$2.1m revenue, or US$1.4m). New Risk • Jul 04
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 26% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.8% average weekly change). Shareholders have been diluted in the past year (15% increase in shares outstanding). Revenue is less than US$5m (AU$2.1m revenue, or US$1.4m). Market cap is less than US$100m (€9.59m market cap, or US$10.4m). New Risk • Mar 31
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 51% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 26% per year over the past 5 years. Shareholders have been substantially diluted in the past year (51% increase in shares outstanding). Minor Risks Revenue is less than US$5m (AU$2.1m revenue, or US$1.3m). Market cap is less than US$100m (€18.9m market cap, or US$20.4m). New Risk • Mar 26
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 13% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 26% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (13% increase in shares outstanding). Revenue is less than US$5m (AU$2.1m revenue, or US$1.4m). Market cap is less than US$100m (€13.8m market cap, or US$15.0m). Tillkännagivande • Mar 22
Rhythm Biosciences Limited has completed a Follow-on Equity Offering in the amount of AUD 2.483947 million. Rhythm Biosciences Limited has completed a Follow-on Equity Offering in the amount of AUD 2.483947 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 24,839,471
Price\Range: AUD 0.1
Security Features: Attached Options
Transaction Features: Rights Offering Tillkännagivande • Feb 09
Rhythm Biosciences Limited has filed a Follow-on Equity Offering in the amount of AUD 6.634278 million. Rhythm Biosciences Limited has filed a Follow-on Equity Offering in the amount of AUD 6.634278 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 66,342,777
Price\Range: AUD 0.1
Security Features: Attached Options
Transaction Features: Rights Offering Tillkännagivande • Dec 29
Rhythm Biosciences Limited Announces Resignation of Rachel David as Non-Executive Director Rhythm Biosciences Limited announced change to its Board of Directors. The Board of Rhythm received the resignation of Dr. Rachel David as a Non-Executive Director of the Company, effective 28 December 2023. The Board thankfully acknowledges Dr. David for her service and contribution to the Company since her appointment just over two years ago (13 December 2021). Dr. David expressed a lack of capacity to manage the current requirements of the Company, given extracurricular events of recent times and other corporate roles and responsibilities. It should be noted Dr. David, retains a demanding full-time executive position, as Chief Executive Officer of Private Healthcare Australia. Rhythm will keep the market notified of plans for its future Board composition. Tillkännagivande • Dec 14
Rhythm Biosciences Ltd Announces the Appointment of James Barrie as Joint Company Secretary, Effective 1 January 2024 Rhythm Biosciences Ltd. announced that it has pointed Mr. James Barrie as Joint Company Secretary of RHY effective 1 January 2024. Mr. Barrie is a professional Company Secretary and Director, and the Board welcomes his assistance moving forward. Ms. Andrea Steele will continue in her role as Joint Company Secretary and General Counsel of RHY and work with Mr. Barrie to ensure a smooth transition into the role. New Risk • Sep 14
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.1% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$7.1m free cash flow). Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 31% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (2.1% increase in shares outstanding). Revenue is less than US$5m (AU$3.1m revenue, or US$2.0m). Market cap is less than US$100m (€47.0m market cap, or US$50.4m). Tillkännagivande • Sep 01
Rhythm Biosciences Limited, Annual General Meeting, Oct 10, 2023 Rhythm Biosciences Limited, Annual General Meeting, Oct 10, 2023, at 11:00 AUS Eastern Standard Time. Location: K & L Gates, Rialto South Tower, Level 25, 525 Collins Street, Melbourne Australia Agenda: To consider statutory requirements for the remuneration report; to consider re-election of Mr Otto Buttula as an Executive Director of the Company; to consider re-election of Mr Louis Panaccio as a Director of the Company; to consider election of Ms Susan MacLeman as Director of the Company; to consider proposed issue of options to Ms Susan MacLeman; to consider approval of 10% placement facility; and to consider adoption of new Employee Incentive Omnibus Plan. New Risk • Sep 01
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$7.1m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$7.1m free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 31% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (2.4% increase in shares outstanding). Revenue is less than US$5m (AU$3.3m revenue, or US$2.1m). Market cap is less than US$100m (€50.8m market cap, or US$54.8m). New Risk • Aug 26
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 36% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Shareholders have been diluted in the past year (2.6% increase in shares outstanding). Revenue is less than US$5m (AU$2.7m revenue, or US$1.7m). Market cap is less than US$100m (€49.2m market cap, or US$53.1m). Recent Insider Transactions • May 16
Executive Chairman recently bought €152k worth of stock On the 12th of May, Otto Buttula bought around 684k shares on-market at roughly €0.22 per share. This transaction amounted to 2.9% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Despite this recent buy, Otto has been a net seller over the last 12 months, reducing personal holdings by €4.2m. Board Change • Apr 20
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non-Executive Director Sue MacLeman was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Feb 22
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non-Executive Director Sue MacLeman was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.